What policy change did the thalidomide crisis impose?

Question

BlackTom AI · Accepted Answer

Thalidomide produced severe limb malformations (phocomelia) in thousands of human infants while early safety testing in common laboratory rodents failed to reveal this risk. That species-specific teratogenicity led regulators to require more rigorous preclinical and clinical testing: specifically, safety testing in at least one rodent and one non-rodent species plus staged clinical trials in humans.

1) Relevant knowledge points and concepts
- Teratogenicity: the ability of a substance to cause birth defects during embryonic development.  
- Species differences: some toxic effects appear in some species but not others; relying on a single species can miss human risks.  
- Regulatory change (Kefauver-Harris Amendments, 1962 and similar laws worldwide): required proof of safety and efficacy, preclinical animal testing, and controlled clinical trials.

2) Step-by-step reasoning
- Historical observation: thalidomide caused widespread birth defects in babies whose mothers took the drug during early pregnancy.  
- Investigation showed that standard rodent tests did not reveal this teratogenic effect, while other species (e.g., rabbits) did display fetal malformations.  
- Because relying on one species produced false negatives, regulators concluded multiple-species testing was necessary to detect risks that are species-specific.  
- Therefore regulatory guidelines were changed to mandate preclinical testing in both a rodent and a non-rodent species to assess toxicity, including teratogenicity, before human trials. Clinical trials (phased and controlled) were also required to demonstrate safety and efficacy in humans.

3) Intermediate steps / specifics
- Preclinical program: acute, subchronic/chronic toxicity, reproductive/teratology studies in one rodent (e.g., rat) and one non-rodent (e.g., rabbit or dog).  
- Only after acceptable animal safety is shown may phased clinical trials (Phase I–III) in humans proceed.

4) Why the correct answer is correct
- The thalidomide crisis directly motivated the requirement for testing in both a rodent and a non‑rodent species plus structured clinical trials, to reduce the chance that a human teratogen would be missed.

5) Why other options are incorrect
- "Test on rodents are sufficient": false—thalidomide is a clear counterexample where rodent tests missed human risk.  
- "Additional test on women during pregnancy": unethical and unsafe; pregnant women are protected populations and cannot be used as initial safety tests.  
- "Chemical analysis test must be performed prior approval": chemical analysis alone cannot predict biological teratogenic effects; functional animal and human studies are required.

6) Conclusion
This explains why the required policy change was testing in one rodent plus one non-rodent species combined with clinical trials, matching the provided answer: One test on rodent + one test on non rodent + clinical trials.

What policy change did the thalidomide crisis impose?单项选择题

类似问题

What does COMP stand for in the European Medicines Agency (EMA)?

The classification requires supplements to go through the same safety and effectiveness testing that the FDA requires for prescription drugs, such as Viagra.

A project has a required return of 12.6 percent, an initial cash outflow of $42,100, and cash inflows of $16,500 in Year 1, $11,700 in Year 2, and $10,400 in Year 4. What is the net present value?

更多留学生实用工具

智能学习助手

风格化写作助手

论文查重助手

文献引用助手

课堂转译助手

课堂笔记助手

Quiz搜索助手

学校历年真题

智能刷题助手

智能匹配练习

希望你的学习变得更简单